Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma

MeSH terms

• ADP-ribosyl Cyclase 1 / antagonists & inhibitors
• Aged
• Antibodies, Monoclonal / administration & dosage
• Antibodies, Monoclonal / adverse effects*
• Antineoplastic Agents, Immunological / administration & dosage
• Antineoplastic Agents, Immunological / adverse effects*
• Antiviral Agents / administration & dosage
• Antiviral Agents / therapeutic use*
• Cytomegalovirus / drug effects*
• Cytomegalovirus / physiology
• Cytomegalovirus Infections / etiology
• Cytomegalovirus Infections / prevention & control
• Dexamethasone / administration & dosage
• Drug Evaluation
• Female
• Ganciclovir / administration & dosage
• Ganciclovir / therapeutic use
• Humans
• Immunocompromised Host
• Lenalidomide / administration & dosage
• Lymphocytes / drug effects
• Male
• Membrane Glycoproteins / antagonists & inhibitors
• Middle Aged
• Multiple Myeloma / complications
• Multiple Myeloma / drug therapy*
• Recurrence
• Retrospective Studies
• Valganciclovir / administration & dosage
• Valganciclovir / therapeutic use
• Virus Activation / drug effects*